Mesoridazine BesylateCAS# 32672-69-8 |
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- Cefoselis Sulfate
Catalog No.:BCC4769
CAS No.:122841-12-7
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 32672-69-8 | SDF | Download SDF |
PubChem ID | 36207 | Appearance | Powder |
Formula | C27H32N2O4S3 | M.Wt | 544.75 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | >21.5mg/mL in DMSO | ||
Chemical Name | benzenesulfonic acid;10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine | ||
SMILES | CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C.C1=CC=C(C=C1)S(=O)(=O)O | ||
Standard InChIKey | CRJHBCPQHRVYBS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C21H26N2OS2.C6H6O3S/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23;7-10(8,9)6-4-2-1-3-5-6/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3;1-5H,(H,7,8,9) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Mesoridazine Besylate Dilution Calculator
Mesoridazine Besylate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8357 mL | 9.1785 mL | 18.357 mL | 36.7141 mL | 45.8926 mL |
5 mM | 0.3671 mL | 1.8357 mL | 3.6714 mL | 7.3428 mL | 9.1785 mL |
10 mM | 0.1836 mL | 0.9179 mL | 1.8357 mL | 3.6714 mL | 4.5893 mL |
50 mM | 0.0367 mL | 0.1836 mL | 0.3671 mL | 0.7343 mL | 0.9179 mL |
100 mM | 0.0184 mL | 0.0918 mL | 0.1836 mL | 0.3671 mL | 0.4589 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fraxamoside
Catalog No.:BCN5247
CAS No.:326594-34-7
- Boc-Ser-OH
Catalog No.:BCC3439
CAS No.:3262-72-4
- Oleuropein
Catalog No.:BCN5246
CAS No.:32619-42-4
- Kaempferol 3-neohesperidoside
Catalog No.:BCN5245
CAS No.:32602-81-6
- GRI 977143
Catalog No.:BCC2401
CAS No.:325850-81-5
- BPIPP
Catalog No.:BCC7730
CAS No.:325746-94-9
- Indiplon
Catalog No.:BCC7720
CAS No.:325715-02-4
- Ascleposide E
Catalog No.:BCN5244
CAS No.:325686-49-5
- 1-Oleoyl lysophosphatidic acid sodium salt
Catalog No.:BCC7792
CAS No.:325465-93-8
- ICA 110381
Catalog No.:BCC6338
CAS No.:325457-99-6
- Sulfo-NHS-SS-Biotin
Catalog No.:BCC3580
CAS No.:325143-98-4
- Ergosta-7,22-dien-3-one
Catalog No.:BCN7088
CAS No.:32507-77-0
- H-Glu(OtBu)-OtBu.HCl
Catalog No.:BCC2934
CAS No.:32677-01-3
- Edpetiline
Catalog No.:BCN6771
CAS No.:32685-93-1
- FAAH inhibitor 1
Catalog No.:BCC4254
CAS No.:326866-17-5
- Shz 1
Catalog No.:BCC6334
CAS No.:326886-05-9
- MHY1485
Catalog No.:BCC6404
CAS No.:326914-06-1
- H-Nle-OH
Catalog No.:BCC3295
CAS No.:327-57-1
- Chlorogenic acid
Catalog No.:BCN5906
CAS No.:327-97-9
- TCS-PIM-1-4a
Catalog No.:BCC5461
CAS No.:327033-36-3
- TDZD-8
Catalog No.:BCC4258
CAS No.:327036-89-5
- VU 0285683
Catalog No.:BCC6154
CAS No.:327056-22-4
- Cyclohexanecarboxylic acid
Catalog No.:BCN3443
CAS No.:98-89-5
- tcY-NH2
Catalog No.:BCC5770
CAS No.:327177-34-4
Diastereotopic analysis of mesoridazine besylate (Serentil).[Pubmed:15290689]
Chirality. 2004 Oct;16(8):534-40.
NMR studies were conducted with the aim of determining the diastereoisomeric ratio of a commercially supplied sample of mesoridazine (MES) and to compare the results with a freshly synthesised sample of MES. The results indicated that the commercially supplied MES consisted almost entirely of one diastereoisomeric pair, which was in agreement with previous findings reported by Eap et al. The synthesised sample of MES was analysed by NMR in two stages: 1) as the initial product isolated as the free base from the direct synthesis, and 2) as the free base isolated from the crystallised besylate salt of the synthetic product. The NMR results show that the initial synthetic product consisted of two equal pairs of diastereoisomers. The diastereoisomeric pairs were further separated by the addition of the chiral shift reagent (R)-(-)-N-(3,5 dinitrobenzoyl)-alpha-benzylamine to reveal equal quantities of all four enantiomers, clearly observed at the methyl sulfoxide proton peak of the NMR scan. The sample obtained from the crystallisation of MES besylate, however, indicated a significant difference, with a diastereoisomeric ratio of 75:25. The results suggest that MES besylate undergoes preferential crystallisation of one pair of diastereoisomers, with the other pair remaining in solution.